Navigation Links
LA BioMed's Dr. Patricia Dickson researching treatments for neurodegenerative disorders
Date:5/30/2012

LOS ANGELES (May 30, 2012) Patricia Dickson, M.D., principal investigator at The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is co-principal investigator of a project that was just awarded a $5.5 million grant from the California Institute for Regenerative Medicine (CIRM). The goal of the project is to develop a stem cell based therapy for the treatment of mucopolysaccharidosis I (MPS I), a fatal pediatric lysosomal storage disease that causes neurodegeneration as well as defects in other major organ systems. Dr. Dickson is working with lead investigator Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children's Research Institute and managing director of the facility's National Human Neural Stem Cell Resource.

For nearly a decade, Dr. Dickson's research at LA BioMed has focused on enzyme replacement therapy for mucopolysaccharidosis, a group of metabolic disorders caused by the absence or malfunctioning of enzymes needed to break down molecules - called glycosaminoglycans - which help build bone, cartilage, connective tissue and other essential parts of the body. As part of this study, she and her colleagues will begin with proof-of-principle experiments for MPS I.

"Dr. Dickson has been at the forefront of mucopolysaccharidosis research for many years, working tirelessly to help develop therapies for MPS I," said David I. Meyer, Ph.D., president and CEO of LA BioMed. "We congratulate her on her continued success, and for her role in this project which could be an important breakthrough for children suffering from neurodegenerative disorders."

"The unique aspect of this research is that it uses a single donor for the transplantation of stem cells into the body and the brain, which allows the best treatment for both physical and neurological disease and avoids rejection of neural stem cell grafts by the host immune system," said Dr. Dickson. "Pediatric neurodegenerative diseases a
'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Sodexo Names Patricia Bellinger to North America Advisory Board
2. What Causes A Person To Be Mentally Ill? Author Who Has Spent Decades Researching Topic Says He Has the Answer
3. Global Basecamps Launches New Website: Researching and Booking Sustainable Travel Has Never Been Easier
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. Charging less for more effective treatments could reduce health care costs while improving health
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Roseville Radiation Oncology Center (ROC) Redefines Efficiency With Elekta VMAT Radiotherapy Treatments
8. Two Sepsis Treatments Look Equally Effective
9. Heart Stem Cells Move Closer to Human Treatments
10. New Ankle Arthritis Treatments Help Boomers Stay Active
11. Larynx preservation treatments result in low instance of severe voice disability, nutritional dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... by HIV/AIDS in South Africa may provide insight on ... issues in other areas of the world, which may ... could lead to successful interventions. , A report ... Nations mentions that due to the HIV/AIDS pandemic, which ... children are at an increased risk for mental health ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have ... Their Dental, Oral, and Craniofacial Manifestations." The complete ... Burke, Alison M. Boyce, Michael Collins, Brian L. ... Scott Ramnitz, Martha J. Somerman and J. Timothy ... the IADR/AADR Journal of Dental Research ...
(Date:4/14/2014)... IL A new study shows that moderate to ... increased risk of stroke, cancer and death. , Results ... moderate to severe obstructive sleep apnea were four times ... four times more likely to have a stroke (HR ... cancer (HR = 3.4), and 2.5 times more likely ...
(Date:4/14/2014)... 10, 2014. John DeLuca, PhD, and Yael Goverover, PhD, ... study how persons with multiple sclerosis (MS) perform everyday ... Reality to Measure Everyday Life Functional Activity in Multiple ... DeLuca is senior VP of Research & Training at ... York University, is a visiting scientist at Kessler Foundation. ...
(Date:4/14/2014)... a UT Dallas study involving serious youth offenders, the answer ... the next seven years: "How long do you think you,ll ... future encourages offending over time., Author Dr. Alex Piquero said ... life ahead of them offend at very high rates and ... to die much later in life offend much less., "In ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2
... , FERNDALE, Mich. and NEW YORK, Aug. ... today the acquisition of PRESCRIBED solutions [CUSTOMIZED SKINCARE]. Since ... among top dermatologists and plastic surgeons with its innovative, customizable ... product Stop the Clock(TM) Triple Action Anti-aging Day ...
... , SAN FRANCISCO, Aug. 14 While natural ... higher than 50 percent and none have been clinically proven to regulate ... e alth International (NHI), a vertically integrated San ... line has been clinically proven to alleviate symptoms of menopause in ...
... minimize the risk as fall looms, experts say , FRIDAY, ... year have another worry besides homework and lunchroom bullies: swine ... early and vigorously to reduce their risk of contracting the ... is going to strike the school-age child and it,s primarily ...
... , , BELLEVUE, Wash., Aug. ... solutions, today announced the new Edifecs5010(TM) Compliance ... and services for healthcare providers, payers, health plans, ISVs, and clearinghouses ... , , Edifecs, the gold standard for HIPAA ...
... , , KENILWORTH, N.J., Aug. ... announced that the U.S. Food and Drug Administration (FDA) has ... in adults and acute treatment of manic or mixed episodes ... in adults. SAPHRIS can be used as a first-line treatment ...
... , NEW YORK, Aug. 14 MS -- ... by AstraZeneca, found that while most patients with asthma understand ... accordingly. , , "This finding demonstrates ... and the necessary steps people should take to achieve better ...
Cached Medicine News:Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 2Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 3Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2Health News:Get Smart About Swine Flu for Back-to-School 2Health News:Get Smart About Swine Flu for Back-to-School 3Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 2Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 4Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 5Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 6Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 7Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 8Health News:Keeping Asthma Under Control 2
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... company developing its Symphony® CGM System as a ... that Robert F. Doman , Executive Chairman ... at "TEN", Noble Financial Capital Markets, Tenth Annual ... make a corporate presentation to prospective corporate partners ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced that it expects revenues for ... $53 million, bringing expected full-year 2013 revenues to ... growth of 87% for 2013 above 2012 reflects ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 ... at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s ... be available live via webcast to interested parties on the ...
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: